We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Associations between ABO non‐identical platelet transfusions and patient outcomes—A multicenter retrospective analysis.
- Authors
Bougie, Daniel W.; Reese, Sarah E.; Birch, Rebecca J.; Bookwalter, Deborah B.; Mitchell, Patrick K.; Roh, David; Kreuziger, Lisa Baumann; Cable, Ritchard G.; Goel, Ruchika; Gottschall, Jerome; Hauser, Ronald George; Hendrickson, Jeanne E.; Hod, Eldad A.; Josephson, Cassandra D.; Kahn, Stacie; Kleinman, Steven H.; Mast, Alan E.; Ness, Paul M.; Roubinian, Nareg H.; Sloan, Steven
- Abstract
Background: Due to platelet availability limitations, platelet units ABO mismatched to recipients are often transfused. However, since platelets express ABO antigens and are collected in plasma which may contain ABO isohemagglutinins, it remains controversial as to whether ABO non‐identical platelet transfusions could potentially pose harm and/or have reduced efficacy. Study Design and Methods: The large 4‐year publicly available Recipient Epidemiology and Donor Evaluation Study‐III (REDS‐III) database was used to investigate patient outcomes associated with ABO non‐identical platelet transfusions. Outcomes included mortality, sepsis, and subsequent platelet transfusion requirements. Results: Following adjustment for possible confounding factors, no statistically significant association between ABO non‐identical platelet transfusion and increased risk of mortality was observed in the overall cohort of 21,176 recipients. However, when analyzed by diagnostic category and recipient ABO group, associations with increased mortality for major mismatched transfusions were noted in two of eight subpopulations. Hematology/Oncology blood group A and B recipients (but not group O) showed a Hazard Ratio (HR) of 1.29 (95%CI: 1.03–1.62) and intracerebral hemorrhage group O recipients (but not groups A and B) showed a HR of 1.75 (95%CI: 1.10–2.80). Major mismatched transfusions were associated with increased odds of receiving additional platelet transfusion each post‐transfusion day (through day 5) regardless of the recipient blood group. Discussion: We suggest that prospective studies are needed to determine if specific patient populations would benefit from receiving ABO identical platelet units. Our findings indicate that ABO‐identical platelet products minimize patient exposure to additional platelet doses.
- Subjects
BLOOD platelet transfusion; BLOOD transfusion; BLOOD groups; RETROSPECTIVE studies; CEREBRAL hemorrhage
- Publication
Transfusion, 2023, Vol 63, Issue 5, p960
- ISSN
0041-1132
- Publication type
Article
- DOI
10.1111/trf.17319